The U.S. Food and Drug Administration (opens in new tab) on Oct. 1 approved the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve for children with congenital pulmonary valve disease. It is the first heart valve designed to be expanded after surgery to keep pace with a child’s growth, and the first valve approved in the U.S. to use polymeric material rather than animal-derived tissue for its leaflets, the agency said. Edwards Lifesciences (opens in new tab) holds the approval; the valve was developed by Autus Valve Technologies Inc., which Edwards bought in February for $128.9 million plus up to $132.5 million in milestone payments, MedTech Dive (opens in new tab) reported, citing a securities filing.

The valve can be implanted as small as about 13 millimeters — the right size for a toddler or preschool-aged child — and later widened with a balloon catheter as the child grows, up to 22 millimeters, comparable to an adult pulmonary valve, the FDA said. Animal-tissue leaflets tend to harden and break down faster in children; the agency said one-year follow-up data suggest the Autus valve’s synthetic leaflets hold up well. Acting FDA Commissioner Kyle Diamantas called the approval “a historic turning point.” Michelle Tarver, director of the FDA’s Center for Devices and Radiological Health, said the valve “gives doctors the option of far fewer trips to the operating room, which may result in better quality of life for these children and their families.” Congenital heart defects affect about 1 in 100 U.S. births, and pulmonary valve atresia and stenosis together affect around 4,200 babies a year, the FDA said, citing the Centers for Disease Control and Prevention.

The approval rests on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients showed acceptable blood-flow performance with no more than mild leakage back through the valve, and all patients had a successful procedure with no deaths, strokes, blood clots requiring additional treatment or other clot-related complications, the FDA said. Three patients had fractures in the valve frame and two had reduced movement of a leaflet; none of those events caused symptoms. Valve performance began to deteriorate in two patients who were starting to outgrow the device; both had their valves expanded without surgery, though the agency said “the experience is limited.” Longer-term studies are underway.

Edwards said the study met its primary safety and effectiveness endpoints, with all patients free of device-related complications through 30 days and no reinterventions on the valve through six months. Among patients who completed one-year follow-up, all had a mean pressure gradient across the valve of 40 mmHg or less, less than moderate regurgitation and no valve reinterventions, the company said, adding that patients will be followed for 10 years. Dr. Emile Bacha, surgeon-in-chief at NewYork-Presbyterian/Columbia University Irving Medical Center and one of the trial’s investigators, said in the company’s announcement that the valve “gives congenital heart teams a new way to think about long-term care planning for pediatric patients who may otherwise face multiple surgeries.” Edwards disclosed that Bacha has received travel and lodging reimbursement from the company for educational activities.

The valve is the first pediatric approval from the FDA’s Total Product Life Cycle Advisory Program and previously received Breakthrough Device designation. It was approved through the premarket approval pathway, the agency’s most stringent route for medical devices.